Citations

Clear

846 citation(s) found for "Li, Min".

487 | MicroRNAs TARGET TUMOR SUPPRESSOR GRK2 IN MALT1‐DEPENDENT DIFFUSE LARGE B‐CELL LYMPHOMA
Cheng, Jing , Smyers, M., Trotta, M., Chandran, Uma , Xia, Min , McAllister‐Lucas, Linda M. , Carleton, Neil M. , Maurer, Lisa M. , Melnick, Ari , Lucas, Peter C.

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70096_487 Get It

Hurting More Than Helping? Decompressive Craniectomy in Patients With Symptomatic Intracerebral Hemorrhage After Mechanical Thrombectomy in Acute Ischemic Stroke: Insights From Stroke Thrombectomy and Aneurysm Registry
Pressman, Elliot , Vakharia, Kunal , Guerrero, Waldo R. , Maier, Ilko , Raai, Ansaar, Jabbour, Pascal , Kim, Joon-Tae , Grossberg, Jonathan A , Wolfe, Stacey Q , Stark, Robert M., Psychogios, Marios‐Nikos , Dye, Justin , Alaraj, Ali , Yoshimura, Shinichi , Ezzeldin, Mohamad , Tanweer, Omar , Polifka, Adam , Siddiqui, Fazeel , Moss, Mark, Brinjikji, Waleed , Dağlıoğlu, Ergün , Williamson, Richard , Altschul, David , Ogilvy, Christopher S. , Crosa, Roberto , Gory, Benjamin , Kan, Peter , Casagrande, Walter, Chowdhry, Shakeel , Stiefel, Michael , Spiotta, Alejandro M , Mokin, Maxim, STAR, on behalf of, Crosa, Roberto , Alaraj, Ali , Altschul, David J , Wolfe, Stacey Quintero , Ogilvy, Christopher S , Sowlat, Mohammad‐Mahdi , Schimmel, Samantha J. , Jabbour, Pascal , Alawieh, Ali , Stark, Robert M., Samaniego, Edgar A , Goyal, Nitin , Fiorella, David , Romano, Daniele G., Navía, Pedro , Cuellar, Hugo, Fragata, Isabel , Mascitelli, Justin R , Osbun, Joshua W , Limaye, Kaustubh , Matouk, Charles , Park, Min S. , Levitt, Michael R. , Gory, Benjamin , Grandhi, Ramesh , Paul, Alexandra R , Mokin, Maxim , STAR, on behalf of

Mayo Clinic

Neurosurgery | June 9, 2025 | Volume: 98 | Issue: 2 | Pages: 345-357

10.1227/neu.0000000000003563 | PMID 40488514 Get It

BACKGROUND AND OBJECTIVES: It remains unclear whether decompressive craniectomy (DC) is beneficial in patients who suffer symptomatic intracerebral hemorrhage (sICH) after acute ischemic stroke (AIS). We sought to study the effect of DC on functional outcomes in patients with sICH after AIS who underwent mechanical thrombectomy (MT). METHODS: Patients with AIS from anterior circulation large vessel occlusion who underwent MT and subsequently developed sICH were identified from the Stroke Thrombectomy and Aneurysm Registry database. The primary outcome was acceptable 90-day functional neurological outcome, defined as modified Rankin scale (mRS) 0-3. Multivariable logistic regression and propensity-score matching were used to identify and quantify risk factors. RESULTS: Of 464 patients identified with sICH after AIS after MT, 97 patients (20.9%) underwent DC. Patients who underwent DC were more likely to be female ( P < .001), younger ( P < .001), have a measured medical comorbidity, have higher baseline mRS ( P = .02), and have higher-grade hemorrhages ( P = .01). At 90 days, 14% of patients had the primary outcome of mRS 0-3 and 56% had died. The primary outcome was observed in 11 patients who underwent DC (11%) and 55 (15%) of those without DC (odds ratio [OR] 0.7, 95% CI 0.4-1.4, P = .40). DC did not affect mRS shift at 90 days ( P = .10) but was associated with lower mortality (OR 0.5, 95% CI 0.3-0.8, P = .01). Multivariable analysis demonstrated that DC decreased the odds of primary outcome (adjusted OR 0.2, 95% CI 0.02-0.9, P = .045), but did not affect mortality ( P = .94), mRS shift ( P = .50), or length of stay ( P = .90). Propensity-matched analysis similarly demonstrated that non-DC patients were more likely to achieve the primary outcome (24% vs 8%, P = .045). CONCLUSION: In patients with sICH after AIS after MT, those selected for DC had less favorable outcomes and similar rates of mortality at 90 days.
The longevity effects of reduced IGF-1 signaling depend on the stability of the mitochondrial genome
Shemtov, Sarah J. , McGann, Eric, Carrillo, Lucy , Lee, Sang‐Min , Anson, Herbert, Chung, Claire S, Anagnostou, Maria‐Eleni, Lai, Guan-Ju, Wan, Junxiang , Vorobyova, Ivetta, Conover, Cheryl A. , Cohen, Pinchas , Kennedy, Scott R. , Goût, Jean-François , Haroon, Suraiya , Vermulst, Marc , Sanchez-Contreras, Monica , Conover, Cheryl A , Thorwald, Max A , Cohen, Pinchas , Kennedy, Scott R , Gout, Jean-François , Haroon, Suraiya , Lee, Sangmin , Hwang, Eric , Verheijen, Bert M. , Sanchez-Contreras, Monica, Thorwald, Max A.

Mayo Clinic

No container title available | June 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.03.656903 | PMID 40501628 Get It

ABSTRACT Suppression of insulin-like growth factor-1 (IGF-1) signaling extends mammalian lifespan and protects against a range of age-related diseases. Surprisingly though, we found that reduced IGF-1 signaling fails to extend the lifespan of mitochondrial mutator mice. Accordingly, most of the longevity pathways that are normally initiated by IGF-1 suppression were either blocked or blunted in the mutator mice. These observations suggest that the pro-longevity effects of IGF-1 suppression critically depend on the integrity of the mitochondrial genome and that mitochondrial mutations may impose a hard limit on mammalian lifespan. Together, these findings deepen our understanding of the interactions between the hallmarks of aging and underscore the need for interventions that preserve the integrity of the mitochondrial genome.
Cobalt toxicity from third-body wear following revision of fractured ceramic-on-ceramic hip bearings with a metal articulation
Terhune, E. Bailey , Sutter, E. Grant , Balkissoon, Rishi , Pallante, Graham D. , Specht, Lawrence M. , Leikin, Jerrold B., Kwon, Young‐Min , Lewallen, David G. , Gerlinger, Tad L. , Jacobs, Joshua J.

Mayo Clinic

The Bone & Joint Journal | June 1, 2025 | Volume: 107-B | Issue: 6 Supple B | Pages: 92-100

10.1302/0301-620x.107b6.bjj-2024-1114.r1 | PMID 40449560 Get It

AimsCeramic-on-ceramic (CoC) articulations in total hip arthroplasty (THA) have the advantage of low wear but the unique risk of fracture. After revision for CoC-bearing fracture, third-body ceramic particles can lead to massive wear of cobalt-chrome (CoCr) bearings, causing extremely elevated blood cobalt. We present a multicentre series of five cases where patients sustained fractures of ceramic liners, were revised using a CoCr articulation, and rapidly developed severe cobalt toxicity.MethodsWe identified five cases of cobalt toxicity after fractured CoC THA treated with revision to CoCr on polyethylene bearings. Mean follow-up was three years (5 to 72 months) after re-revision to remove the CoCr bearing.ResultsSymptoms of cobalt toxicity occurred at a mean ten months (6 to 12) after revision for ceramic fracture. All patients developed vision and hearing loss, balance difficulties, and peripheral neuropathy. Several had cardiomyopathy, endocrine abnormalities, and local skin discolouration. Only two reported hip pain. Repeat revision for recognized cobalt toxicity occurred at a mean 22 months after revision for ceramic fracture. Mean serum cobalt level at re-revision was 991 ng/ml (normal value < 1 ng/ml; 734 to 1,302). All CoCr femoral heads exhibited massive wear, and deep tissues showed prominent metal staining. Treatment consisted of debridement and revision to a ceramic femoral head with highly cross-linked polyethylene (HXLPE) liner. Serum cobalt improved to a mean 25 μg/l (1 to 76) at final follow-up. All patients reported partial improvement in vision and hearing, however their peripheral neuropathy and balance difficulties did not recover.ConclusionSystemic cobalt toxicity is a devastating complication of ceramic-bearing fracture in THA treated with CoCr bearings, which may not present with hip symptoms. The diagnosis of this syndrome of systemic cobalt toxicity was significantly delayed following systemic symptoms in this series. Debridement and re-revision to a ceramic-on-HXLPE bearing leads to improvement, but not full resolution, of cobalt toxicity complications.Cite this article: Bone Joint J 2025;107-B(6 Supple B):92–100.
Real-world cardiovascular outcomes of carfilzomib in relapsed or refractory multiple myeloma.
Sorajja, Dan , Tan, Jia Yi , Vignarajah, Aravinthan , Tan, Min Choon , Lee, Kwan , Hilal, Talal

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e19524 Get It

e19524 Background: Carfilzomib, a second-generation proteasome inhibitor, has emerged as one of the therapeutic agents in the treatment of relapsed or refractory multiple myeloma (MM). Despite its known cardiotoxicity, real-world data on its long-term cardiovascular outcomes remain limited. This study aimed to evaluate the real-world cardiovascular outcomes in patients with relapsed or refractory MM treated with carfilzomib. Methods: We utilized the TriNetX network to identify patients (≥18 years old) with relapsed or refractory MM between January 1, 2014, and January 1, 2019. We further categorized the patients into two groups: patients exposed to carfilzomib and patients not exposed to carfilzomib. Inclusion in the carfilzomib group required exposure to carfilzomib during the 5-year study period. Propensity score matching was performed to match these two groups based on comorbidities, medications, baseline hemoglobin A1c, low-density lipoprotein, and left ventricular ejection fraction to produce two comparable cohorts. The study outcomes were cardiovascular outcomes, including acute heart failure, acute myocardial infarction, cerebrovascular accident, acute venous thromboembolism, all-cause hospitalization, and all-cause mortality over the 5-year follow-up duration. Results: A total of 151,802 patients with relapsed or refractory MM were identified, including 6,386 patients (mean age 64.8 ± 10.6 years) who were exposed to carfilzomib and 145,416 patients (mean age 66.1 ± 12.7 years) who were not. After propensity score matching, there were 4,559 (65.3 ± 10.8 years of age, 44.7% female, 18.2% African American [AA]) patients who were exposed to carfilzomib and 4,559 patients who were not (65.2 ± 12.2 years of age, 45.1% female, 17.0% AA). Exposure to carfilzomib was associated with higher odds of acute heart failure (adjusted odds ratio [aOR]: 1.61; 95% CI: 1.48-1.77, P < 0.001), acute myocardial infarction (aOR: 1.24; 95% CI: 1.03-1.48, P = 0.020), cerebrovascular accident (aOR: 1.97; 95% CI: 1.47-2.64, P < 0.001), acute venous thromboembolism (aOR: 1.79; 95% CI: 1.58-2.03, P < 0.001), all-cause hospitalizations (aOR: 1.91; 95% CI: 1.75-2.09, P < 0.001), and all-cause mortality (aOR: 1.97; 95% CI: 1.80-2.16, P < 0.001). Conclusions: Patients with relapsed or refractory MM who were exposed to carfilzomib had poorer cardiovascular outcomes compared to those who did not.
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR
Wudhikarn, Kitsada , Chen, Min , Baird, John H. , Gowda, Lohith , Rangarajan, Hemalatha G. , Abid, Muhammad Bilal , Kharfan‐Dabaja, Mohamed A. , Ganguly, Siddhartha , Young, Jo‐Anne H. , Sharma, Akshay , Modi, Dipenkumar , Salem, Baheyeldin , Vergidis, Paschalis , Smith, Melody , Boghdadly, Zeinab El , Dandoy, Christopher E. , Huppler, Anna R. , Chemaly, Roy F. , Hill, Joshua A. , Riches, Marcie , Herr, Megan M. , Martens, Michael J , Baird, John , Rangarajan, Hemalatha G , Abid, Muhammad Bilal , Kharfan-Dabaja, Mohamed A , Young, Jo-Anne H , Sharma, Akshay , Fatobene, Giancarlo , Jain, Tania , Modi, Dipenkumar , Grover, Natalie S , Salem, Baheyeldin , Batista, Marjorie Vieira , Vergidis, Paschalis , Yin, Dwight E , Kelkar, Amar H , Nishihori, Taiga , Holter Chakrabarty, Jennifer , Gergis, Usama , Smith, Melody , Dandoy, Christopher E , Murthy, Hemant S , Huppler, Anna R , Perales, Miguel-Angel , Chemaly, Roy F , Hill, Joshua A , Auletta, Jeffery J , Martens, Michael J. , Williams, Kirsten M. , Jain, Tania , Kanakry, Christopher G. , Grover, Natalie S. , Beitinjaneh, Amer , Nishihori, Taiga , Holter‐Chakrabarty, Jennifer , Murthy, Hemant S. , Perales, Miguel‐Angel , Auletta, Jeffery J.

Mayo Clinic

Blood Advances | May 28, 2025 | Volume: 9 | Issue: 21 | Pages: 5460-5472

10.1182/bloodadvances.2025016141 | PMID 40435511 Get It

Abstract Infection is increasingly recognized as a significant cause of morbidity and mortality in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) receiving CD19 chimeric antigen receptor (CAR) T-cell therapy. The current study analyzed the natural history, risk factors, and outcomes of infection in 3350 patients with R/R LBCL receiving commercial CD19 CAR T-cell therapy (n = 2804 axicabtagene ciloleucel [axi-cel], n = 546 tisagenlecleucel) from December 2017 to June 2022. Infection developed in 834 patients (24.9%) within 100 days after infusion, resulting in an infection density of 0.43 per 100 patient days and a 100-day cumulative incidence of 22%. Bacterial, viral, and fungal infections were recorded in 527 (15.7%), 374 (11.2%), and 108 patients (3.2%), respectively, with corresponding infection densities of 0.23, 0.15, and 0.04 per 100 patient days. After a 24-month median follow-up, 1482 patients (44%) had died, with infection as the primary cause in 173 cases (12%). The 100-day infection-related mortality (IRM) was 1.6% (95% confidence interval, 1.2-2.0). Patients with a Karnofsky performance score of ≤80, infection history before CAR T-cell therapy, axi-cel therapy, severe cytokine release syndrome (grade ≥3), and severe immune effector cell–associated neurotoxicity syndrome (grade ≥3) had increased infection risk. Infections within 100 days were an independent risk factor for inferior overall survival beyond day 100 after CD19 CAR T-cell therapy. In conclusion, study results show a significant incidence of infection and IRM in patients with R/R LBCL treated with CD19 CAR T-cell therapy. Furthermore, results identify patients at a heightened risk of infection, offering insights to guide potential interventions aimed at mitigating infection and improving patient outcomes after CAR T-cell therapy.
Long-term follow-up of the phase 2 ELM-2 study: Odronextamab for patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL).
Jagadeesh, Deepa , Poon, Michelle, Yi, ShuHua, Cai, Jingxian, Brouwer‐Visser, Jurriaan , Chaudhry, Aafia, Ambati, Srikanth, Kim, Tae Min, Taszner, Michał , Chong, Geoffrey , Novelli, Silvana , Cho, Seok‐Goo , Villasboas, José C. , Merli, Michele , Ubieto, Ana Jiménez , Tessoulin, Benoit , Tucker, David , Walewski, Jan , Mohamed, Hesham , Kim, Tae Min

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 7049-7049

10.1200/jco.2025.43.16_suppl.7049 Get It

7049 Background: Odronextamab, an investigational off-the-shelf CD20×CD3 bispecific antibody, demonstrated compelling efficacy and a generally manageable safety profile in heavily pretreated pts with R/R FL in the primary analysis of the Phase 2 ELM-2 study (NCT03888105; Kim TM, et al. Ann Oncol 2024). We present updated efficacy and safety data for odronextamab in pts with R/R FL from ELM-2 after >2 yrs follow-up. Methods: Odronextamab was administered intravenously until disease progression/unacceptable toxicity, with Cycle (C) 1 step-up dosing to help mitigate cytokine release syndrome (CRS) risk, as reported previously. Pts with a complete response (CR) for ≥9 months (mo) switched from maintenance dosing Q2W to Q4W. Primary endpoint: objective response rate (ORR) per Lugano criteria by independent central review (ICR); secondary endpoints: CR rate, duration of response (DOR), progression-free survival (PFS), overall survival (OS). Results: At the updated data cutoff (Aug 15, 2024), 157 pts with centrally confirmed R/R FL Grade (Gr) 1–3a were enrolled. Median no. of treatment cycles: 19.0 (range 0.1–117.3); 96.2% (n = 151) and 82.8% (n = 130) of pts completed C1 and C4, respectively. The global cohort comprised 128 pts evaluable for efficacy. At a median efficacy follow-up of 28.3 mo, ORR was 80.5% (n = 103) by ICR and CR rate was 74.2% (n = 95); 92.2% of responders achieved CR. Responses were durable (median DOR, 26.0 mo; median duration of CR, 32.2 mo). ORR was consistent across high-risk subgroups (Follicular Lymphoma International Prognostic Index score 3–5, 78.4%; progression of disease within 2 yrs of frontline therapy, 81.0%). Median PFS was 23.0 mo (estimated 36-mo PFS rate, 37.5%), and median OS was 54.2 mo (estimated 36-mo OS rate, 62.6%). Median PFS was longer in pts who were minimal residual disease (MRD) negative (42.4 mo) versus MRD positive (21.6 mo) at Week 12. Of 47/128 pts who switched to Q4W dosing, 32 remained in CR. The odronextamab long-term safety profile was consistent with the primary analysis. All 157 pts had TEAEs (Gr ≥3, 86.0%), and 15.3% discontinued treatment due to TEAEs (most common: COVID-19 infection, 2.5%). With 0.7/4/20 mg step-up dosing (n = 89), CRS events were mostly low grade (Gr 1, 46.1%; Gr 2, 13.5%; Gr 3, n = 1; Gr ≥4, n = 0), occurred mostly in C1, and resolved in a median of 8.4 hrs. Immune effector cell-associated neurotoxicity syndrome was reported in one pt (Gr 2). Infections were reported in 79.0% of pts (124/157; Gr ≥3, 42.0%). COVID-19-related infections were reported in 38.2% of pts (Gr 5, 5.7%). Conclusions: With longer follow-up, odronextamab demonstrated durable responses in heavily pretreated pts with R/R FL from ELM-2, with robust efficacy in those with high-risk features, and a generally manageable safety profile. Overall, these compelling results support odronextamab as a potential off-the-shelf treatment option for pts with R/R FL. Clinical trial information: NCT03888105 .
Consensus Statement on Robotic Nipple Sparing Mastectomy Expert Panel
Ryu, Jai Min , Mok, Chi Wei , Toesca, Antonio , Lai, Hung‐Wen , Kuo, Wen‐Ling , Cheng, Fiona Tsui-Fen , Song, Seung Yong , Johnson, Jeffrey , Shin, Hyukjai , Park, Hyung Seok , Johnson, Jeffrey E , Cheng, Fiona Tsui-Fen

Mayo Clinic

Journal of Breast Cancer | May 19, 2025 | Volume: 28 | Issue: 3 | Pages: 180

10.4048/jbc.2025.0030 | PMID 40432351 Get It

Clinical Validation and Post-Implementation Performance Monitoring of a Neural Network-Assisted Approach for Detecting Chronic Lymphocytic Leukemia Minimal Residual Disease by Flow Cytometry
Seheult, Jansen N. , Otteson, Gregory E., Weybright, Matthew J. , Timm, Michael, Han, Wenchao, Horna, Pedro , Olteanu, Horatiu , Shi, Min , Timm, Michael M, Horna, Pedro , Olteanu, Horatiu , Shi, Min , Seheult, Jansen N , Jevremović, Dragan

Mayo Clinic

Cancers | May 19, 2025 | Volume: 17 | Issue: 10 | Pages: 1688

10.3390/cancers17101688 | PMID 40427185 Get It

Background: Flow cytometric detection of minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) is complex, time-consuming, and subject to inter-operator variability. Deep neural networks (DNNs) offer potential for standardization and efficiency improvement, but require rigorous validation and monitoring for safe clinical implementation. Methods: We evaluated a DNN-assisted human-in-the-loop approach for CLL MRD detection. Initial validation included method comparison against manual analysis (n = 240), precision studies, and analytical sensitivity verification. Post-implementation monitoring comprised four components: daily electronic quality control, input data drift detection, error analysis, and attribute acceptance sampling. Laboratory efficiency was assessed through a timing study of 161 cases analyzed by five technologists. Results: Method comparison demonstrated 97.5% concordance with manual analysis for qualitative classification (sensitivity 100%, specificity 95%) and excellent correlation for quantitative assessment (r = 0.99, Deming slope = 0.99). Precision studies confirmed high repeatability and within-laboratory precision across multiple operators. Analytical sensitivity was verified at 0.002% MRD. Post-implementation monitoring identified 2.97% of cases (26/874) with input data drift, primarily high-burden CLL and non-CLL neoplasms. Error analysis showed the DNN alone achieved 97% sensitivity compared to human-in-the-loop-reviewed results, with 13 missed cases (1.5%) showing atypical immunophenotypes. Attribute acceptance sampling confirmed 98.8% of reported negative cases were true negatives. The DNN-assisted workflow reduced average analysis time by 60.3% compared to manual analysis (4.2 ± 2.3 vs. 10.5 ± 5.8 min). Conclusions: The implementation of a DNN-assisted approach for CLL MRD detection in a clinical laboratory provides diagnostic performance equivalent to expert manual analysis while substantially reducing analysis time. Comprehensive performance monitoring ensures ongoing safety and effectiveness in routine clinical practice. This approach provides a model for responsible AI integration in clinical laboratories, balancing automation benefits with expert oversight.
Amyloid beta peptides inhibit glucose transport at the blood-brain barrier by disrupting the insulin-AKT pathway
Wang, Lushan , Curran, Geoffry L., Zhong, Rui , Zheng, Xue , Veerareddy, Vaishnavi, Thieschafer, Josslen S., Min, Hoon‐Ki , Lowe, Val J. , Kandimalla, Karunya K. , Kandimalla, Karunya K , Min, Hoon-Ki Paul , Xue, Zheng, Li, Ling

Mayo Clinic

Journal of Cerebral Blood Flow & Metabolism | May 15, 2025 | Volume: 45 | Issue: 10 | Pages: 1961-1979

10.1177/0271678x251332493 | PMID 40370301 Get It

Abstract Molecular mechanisms underlying disruptions in brain glucose uptake and metabolism, linked with cognitive decline in Alzheimer’s disease (AD) patients, are only partially understood. This study investigated how soluble amyloid beta (sAβ) peptides affect glucose transport at the blood-brain barrier (BBB), the primary portal for glucose entry into the brain. We demonstrated that [ 18 F]-fluorodeoxyglucose ( 18 FDG) uptake is reduced in sAβ overproducing APP,PS1 transgenic mice compared to wild-type mice. Moreover, the influx rate of 18 FDG decreased in sAβ40 or sAβ42 pre-infused mice, highlighting the inhibitory effect of sAβ peptides on glucose transport at the BBB. Consistently, the expression of GLUT1, the primary glucose transporter at the BBB, is reduced in polarized human cerebral microvascular endothelial cell (hCMEC/D3) monolayers upon exposure to sAβ peptides and in Aβ-laden cerebral vasculature in vivo. The study further examined the influence of sAβ on the insulin-AKT pathway, known to regulate glucose uptake through modulation of thioredoxin-interacting protein (TXNIP) expression. Results showed that sAβ peptides suppress AKT phosphorylation and reduce GLUT1 expression by upregulating TXNIP levels in hCMEC/D3 monolayers. Co-incubation of resveratrol with sAβ peptides reduced TXNIP expression and rectified reductions in GLUT1 expression. In summary, toxic sAβ impairs BBB glucose transport by disrupting the insulin/AKT/TXNIP axis.